high-risk idiopathic membranous nephropathy
Conditions
Interventions
test group:tacrolimus
prednisone
Sponsors
The First Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1: Age =18 years old 2: Biopsy-confirmed diagnosis of MN within 24 months prior to enrollment 3: Diagnosis of IMN after exclusion of secondary, genetic factors 4: Diagnosed as high risk by KDIGO 2021 risk stratification for disease progression 5: No use of any immunosuppressive agents (e.g., rituximab, steroids, alkylating agents, calcineurin inhibitors, synthetic ACTH, MMF, azathioprine, etc.) within the previous 6 months 6: Serum creatinine level < 133 umol/L 7: Agree to sign an informed consent form and follow medical advice
Exclusion criteria
Exclusion criteria: 1: Presence of active infectious diseases in the patient (tested before inclusion in the study): e.g. hepatitis B and C, HIV, tuberculosis and syphilis 2: Patient is diagnosed with secondary MN (e.g., systemic lupus erythematosus (SLE)) 3: Patient has malignant tumor 4: Fasting blood glucose > 6.2 mmol/L 5: Presence of renal vein thrombosis detected by renal ultrasound (US) or CT scanning 6: Patient is pregnant or breastfeeding 7: Presence of life-threatening complications, such as heart failure or active gastrointestinal bleeding 8: Researchers determine other situations that are not suitable for inclusion in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission rate at 24 weeks of treatment (percent of patients with CR+PR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of patients with recurrence of IMN during the maintenance treatment period;Remission rate at 41248 weeks of treatment (percent of patients with CR+PR);Adverse event rate;PLA2R titers at 4, 12, 24, and 48 weeks of treatment; | — |
Countries
China
Contacts
Public ContactHeng Li
The First Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed